menu
    • menu
    [{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Not Applicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Not Applicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"JIN-A02","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Not Applicable"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Yuhan Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"JIN-A04","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"J Ints Bio","amount2":0.33000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"J Ints Bio \/ Yuhan Corporation","highestDevelopmentStatusID":"4","companyTruncated":"J Ints Bio \/ Yuhan Corporation"},{"orgOrder":0,"company":"J Ints Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"JIN-A02","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"J Ints Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"J Ints Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"J Ints Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by J Ints Bio

    Menu

    J Ints Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            JIN-A02 Shows Tumor Reductions in Ongoing Phase 1 Study with Brain Metastasis

                            Details : JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S. Currently, it is being evaluated in the early-stage clinical trial studies for the treatment of NSCLC.

                            Brand Name : JIN-A02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2024

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JIN-A04

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Yuhan Corporation

                            Deal Size : $325 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Yuhan Corporation and J INTS BIO Inked a Licensing Agreement for A New Drug Candidate Targeting HER2 NSCLC

                            Details : The license agreement is for JIN-A04, an oral Tyrosine Kinase Inhibitor (TKI) targeting non-small cell lung cancer carrying HER2 mutations. There is currently no oral drug approved to date.

                            Brand Name : JIN-A04

                            Molecule Type : Undisclosed

                            Upfront Cash : $1.9 million

                            May 31, 2023

                            Lead Product(s) : JIN-A04

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Yuhan Corporation

                            Deal Size : $325 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            J INTS BIO, Poster Presentation of Further Preclinical Data of Its Novel Oral 4th Generation EGFR-TKI 'JIN-A02...

                            Details : JIN-A02 is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC. 'JIN-A02' have a high brain penetrance and is expected to become the most promising 4th-generation EGFR TKI in NSCLC patients with limited or no viable tre...

                            Brand Name : JIN-A02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2022

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at th...

                            Details : JIN-A02 is a novel orally administered EGFR TKI that targets NSCLC cancers harboring C797S mutation, showed strong inhibitory activities against NSCLC cancer cell-lines harboring double and triple mutations with C797S mutations in in-vitro studies.

                            Brand Name : JIN-A02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 14, 2022

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed

                            J Ints Bio

                            South Korea arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            J INTS BIO 4th Generation EGFR TKI (JIN-A02) US FDA Phase 1/2 IND submission completed

                            Details : JIN-A02 is a novel orally administered 4th generation EGFR TKI that targets NSCLC cancers harboring C797S mutation. C797S is a mutation that occur after the use of 3rd generation EGFR TKIs such as Osimertinib and Lazertinib, resulting in tumor resistance...

                            Brand Name : JIN-A02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 03, 2022

                            Lead Product(s) : JIN-A02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth